Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers

Phase 3

Completed

Conditions: Poliomyelitis

Interventions: Biological: PoliorixTM
Biological: Infanrix+Hib

Registration Number: NCT01323647

Lead Sponsor: GlaxoSmithKline

Brief Summary: This study aims to evaluate the persistence of anti-poliovirus antibodies in toddlers aged 18 months who were primed with oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in the primary study. The study will also assess the immunogenicity and reactogenicity of a booster dose of IPV in subjects primed with three doses of IPV.

Detailed Description: All subjects will also receive a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) at Day 0. This vaccine will be provided as part of the local standard of care and will not be associated with any study endpoint.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 957

Inclusion Criteria

Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.
Subjects who received the complete three-dose primary vaccination course in study NCT01021293.
Healthy male or female toddlers 18 to 24 months of age at the time of Visit 1 (Day 0).
Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.
Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria

Child in care.
Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine(s), or planned use during the study period.
Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to Visit 1 (Day 0).
Administration of immunoglobulins and/or any blood products within the 3 months preceding Visit 1 (Day 0) or planned administration during the study period.
Administration of a vaccine not foreseen by the study protocol within 30 days of Visit 1 (Day 0) or planned administration during the study period.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Evidence of previous booster vaccination against poliomyelitis or the disease since the conclusion visit of Study NCT01021293.
History of seizures or progressive neurological disease.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
Major congenital defects or serious chronic illness.
Acute disease and/or fever at the time of enrolment.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Infanrix+Hib	Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
Group A	PoliorixTM	Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
Group B	Infanrix+Hib	Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.

Primary Outcome Measures

Name	Time	Method
Antibody Titers Against Poliovirus Type 1, 2 and 3.	Before booster vaccination.	Antibody titers were summarized by geometric mean titers (GMTs) with their 95% CIs.
Number of Subjects Seroprotected for Poliovirus Types 1, 2 and 3 Antibodies Above the Cut-off Value	Before booster vaccination.	A seroprotected subject was defined as a vaccinated subject whose antibody titer is greater than or equal to (≥) 8 ED50.
Antibody Titers Against Poliovirus Type 1, 2 and 3	One month after Poliorix™ booster vaccination.	Antibody titers were summarized by geometric mean titers (GMTs) with their 95% confidence intervals (CIs). This outcome measure concerns subjects in the Poliorix Group only.

Secondary Outcome Measures

Name	Time	Method
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.	Within 4-days (Days 0-3) post Poliorix™ booster vaccination.	Solicited general symptoms assessed include drowsiness, irritability, loss of appetite and fever \[defined as axillary temperature ≥ 37.1 degrees Celsius (°C)\]. Any = occurence of any general symptom regardless of their intensity grade or relationship to study vaccine. Grade 3 drowsiness = drowsiness that prevented normal activities. Grade 3 fever = fever (axillary temperature) \>39.0°C. Grade 3 irritability = crying that could not be comforted/ prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as causally related to the vaccination. This outcome measure concerns subjects in the Poliorix Group only.
Number of Subjects With Any and Grade 3 Solicited Local Symptoms	Within 4-days (Days 0-3) post Poliorix™ booster vaccination.	Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Cry when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site. This outcome measure concerns subjects in the Poliorix Group only.
Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)	Within the 31-day (Days 0-30) follow-up period after the Poliorix™ booster vaccination.	An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as an adverse event (AE) reported in addition to those solicited during the clinical study. Any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. This outcome measure concerns subjects in the Poliorix Group only.
Number of Subjects With Serious Adverse Events (SAEs)	During the entire study period (Day 0 to Month 1).	Serious adverse events (SAEs) assessed include medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.